The annual impact of seasonal influenza in the US: Measuring disease burden and costs☆
Introduction
Influenza has attained an unprecedented degree of attention in recent years as a result of disruptions in vaccine supply and distribution, and concerns about the nation's ability to respond to an influenza pandemic. Influenza has a long history, however, of causing substantial morbidity and mortality nearly every year. Despite vaccination recommendations targeted to high-risk groups and their contacts, an annual average of 36,000 deaths and over 200,000 hospitalizations occurred during the 1990s [1]. Illness severity and mortality are greatest in high-risk groups, and so are the associated healthcare costs and productivity losses [1]. In addition, costs and lost productivity among non-high-risk groups are not trivial [1], [2]. In order to reduce the burden of influenza, various vaccination strategies have been proposed; most recently the Advisory Committee on Immunization Practices extended the recommendation to include children 24–59 months [1].
Economic considerations are an essential ingredient to effectively guide policy-making for influenza vaccination. Numerous studies have considered the cost effectiveness of influenza vaccination [3], [4], [5]. However, only one previous study systematically estimated the economic impact of influenza in the United States and that study focused on the impact of pandemic influenza [2]. This study estimates the annual impact of seasonal influenza in the US by measuring disease burden and associated medical and indirect costs. Projected costs were estimated by age and risk strata. We examined direct medical expenses to treat the disease and its sequelae as well as indirect costs from lost productivity and lives lost due to premature death. Our estimate of the average cost of an influenza season is based on 2003 US population demographics.
Section snippets
Methods
We used both payer and societal perspectives to estimate the economic burden of influenza in the US. The economic burden of influenza at the population level is a function of the cost per case of influenza and the number of cases. In order to account for variation in costs by age and risk of severe complications from influenza, we estimated costs for five age groups: <5 years, 5–17, 18–49, 50–64, and ≥65. In addition, we distinguished the cost for high-risk and low-risk groups. Finally, we
Results
Consistent with earlier studies, results indicated 24.7 million cases of influenza annually with about 31.4 million attributed outpatient visits based on 2003 population demographics. Case-patients accounted for 334,185 hospitalizations and about 3.1 million hospitalized days (Table 3, Table 4). Days of productivity lost due to illness amounted to 44.0 million (Table 4). We estimated 41,008 deaths in case-patients amounting to 610,656 life years lost; the majority of deaths occurred in the older
Discussion
Our results indicate that the annual economic burden of influenza remains very high. The total annual economic burden of influenza epidemics in the United States across all age groups was $87.1 billion (C.I., $47.2 billion, $149.5 billion) using the VSL method to value lost lives including direct medical costs of $10.4 billion (C.I., $4.1 billion, $22.2 billion). The annual burden per capita ranged between $92 (considering only lost earnings) and $299 (including lost lives). When considered from the
Acknowledgements
We acknowledge the insightful comments of Drs. Andrea Molinari, Martin Meltzer, Abigail Shefer, Fangjun Zhou, and Mary McCauley. Potential conflict of interest: all authors: no conflict. Funding: This research was conducted while the authors were employed by the Centers for Disease Control and Prevention (CDC). N.A. Molinari and I. Ortega-Sanchez are economists at NCIRD; M. Messonnier is lead economist at NCIRD; W. Thompson is a senior epidemiologist at OD-OCSO; P. Wortley is a medical officer
References (54)
- et al.
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period
Vaccine
(1997) - et al.
Influenza- and RSV-associated hospitalizations among adults
Vaccine
(2007) - et al.
Safety, efficacy, and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults
Vaccine
(2001) - et al.
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis
Vaccine
(2002) - et al.
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Lancet
(2005) - et al.
Influenza vaccination in elderly people
Lancet
(2005) - et al.
Strengthening the nation's influenza vaccination system: a National Vaccine Advisory Committee assessment
Am J Prev Med
(2005) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR
(2006)- et al.
The economic impact of pandemic influenza in the United States: priorities for intervention
Emerg Infect Dis
(1999) - et al.
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B
Health Technol Assess
(2003)
An intranasal influenza vaccine for the prevention of influenza in healthy children was cost effective
Evid Based Med
Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial
JAMA
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
J Infect Dis
Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study
J Infect Dis
Vital statistics mortality data, multiple cause detail, 1972–1998
Impact of type A influenza on children: a retrospective study
Am J Pub Health
2000 National Hospital Discharge Survey
Adv Data
Surveillance for influenza—United States, 1994–95, 1995–96, and 1996–97 seasons
MMWR CDC Surveill Summ
Influenza and the rates of hospitalization for respiratory disease among infants and young children
N Engl J Med
Influenza-associated hospitalizations in the United States
JAMA
Mortality associated with influenza and respiratory synctial virus in the United States
JAMA
Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates
Natl Vital Stat Rep
Health burden of influenza in healthy adults aged 18–49 years
Incidence of outpatient visits and hospitalizations related to influenza in infants and young children
Pediatrics
Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts
JAMA
Cited by (1391)
Understanding if the reward is worth the influenza risk: The true cost of showing pigs
2024, Preventive Veterinary MedicineExplainable influenza forecasting scheme using DCC-based feature selection
2024, Data and Knowledge EngineeringEthnobotanical Investigation of Plants Used for Respiratory Tract Infections in Pirot District (Southeastern Serbia)
2023, Journal of Herbal MedicineDiscovery of a potent inhibitor targeting the cap-binding domain of the PB2 subunit of influenza RNA-dependent RNA polymerase
2023, Biochemical and Biophysical Research CommunicationsExploring health seeking behaviors for common cold management
2023, Exploratory Research in Clinical and Social Pharmacy
- ☆
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, US Department of Health and Human Services.